MAFP Testifies on Opioid Legislation Before House Panel

On September 27, MAFP Advocacy Committee Vice Chairman Glenn Dregansky, DO, FAAFP (Kalamazoo) testified before the Michigan House Health Policy Committee on the opioid epidemic and the state’s response to the growing public health crisis.

In his remarks, Dr. Dregansky recognized the ongoing efforts of the Michigan Department of Licensing and Regulatory Affairs to partner with the physician and healthcare provider communities to successfully implement a new prescription and improved drug monitoring platform, upgrading the system we know as MAPS, and to work towards integrating MAPS into electronic medical records.

Dr. Dregansky also recognized the Michigan Department of Health and Human Services' work in looking at the issue more holistically and organizing a health systems-driven approach. The Academy did weigh in with concerns regarding two bill packages currently under consideration that could have a detrimental effect on patient access to legitimate pain medication and create an unnecessary administrative burden on prescribers.

Senate Bill 166/167 would require all prescribers to query MAPS when prescribing controlled substances to patients, with the exception of prescriptions dispensed in a hospital setting. MAFP also raised concerns about Senate Bill 274, which would restrict the prescribing of an opioid for acute pain to a seven-day supply within a seven-day period. The Academy offered amendatory changes to the bills that seek to address concerns without dampening the bills’ intended purposes. Whether any of the proposed changes will ultimately be woven into final legislation remains influx.

SB 166/167 and SB 274 passed the Senate prior to the legislature’s adjournment for the summer and the House committee is likely to vote on them when they convene again on Wednesday, October 4.